MA41790B1 - Dérivé de morphinane - Google Patents
Dérivé de morphinaneInfo
- Publication number
- MA41790B1 MA41790B1 MA41790A MA41790A MA41790B1 MA 41790 B1 MA41790 B1 MA 41790B1 MA 41790 A MA41790 A MA 41790A MA 41790 A MA41790 A MA 41790A MA 41790 B1 MA41790 B1 MA 41790B1
- Authority
- MA
- Morocco
- Prior art keywords
- represent hydrogen
- ring
- atoms
- carbon atoms
- carbon atom
- Prior art date
Links
- 150000003809 morphinane derivatives Chemical class 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Dérivé de morphinane représenté par la formule générale (i) suivante : (où r1 représente l'hydrogène, un alkyle en c1-10, un cycloalkylalkyle où le fragment cycloalkyle a 3 à 6 atomes de carbone, et le fragment alkylène a 1 à 5 atomes de carbone, etc.,r2 représente cycle hétérocyclique contenant 1 à 4 hétéroatomes choisis parmi n, o et s et au moins un atome de carbone en tant qu'atomes constituant le cycle, contenant au moins un ensemble d'atomes constituant le cycle adjacents liés par une double liaison, et en outre substitué par au moins un groupe oxo,y se lie à un atome de carbone en tant qu'atome constituant le cycle de r2, r3, r4 et r5 représentent l'hydrogène ; hydroxy, etc., r6a et r6bre représentent l'hydrogène, etc., r7 et r8 représentent l'hydrogène, etc., r9 et r10, qui sont identiques ou différents, représentent l'hydrogène, etc.,x représente o ou ch2, ety représente c(=o)),un tautomère ou stéréoisomère du composé, ou un sel pharmaceutiquement acceptable de celui-ci, ou un solvate de celui-ci est utilisé comme anxiolytique médicament, antidépresseur, etc
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015054079 | 2015-03-17 | ||
| PCT/JP2016/058475 WO2016148232A1 (fr) | 2015-03-17 | 2016-03-17 | Dérivé de morphinane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41790A MA41790A (fr) | 2021-06-02 |
| MA41790B1 true MA41790B1 (fr) | 2022-02-28 |
Family
ID=56919074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41790A MA41790B1 (fr) | 2015-03-17 | 2016-03-17 | Dérivé de morphinane |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10442802B2 (fr) |
| EP (2) | EP3974430A1 (fr) |
| JP (5) | JP6692345B2 (fr) |
| KR (2) | KR102813010B1 (fr) |
| CN (3) | CN113292559B (fr) |
| AU (2) | AU2016234222C1 (fr) |
| BR (1) | BR112017019805B1 (fr) |
| CA (1) | CA2979023C (fr) |
| CY (1) | CY1124908T1 (fr) |
| DK (1) | DK3272750T3 (fr) |
| ES (1) | ES2904511T3 (fr) |
| HU (1) | HUE057266T2 (fr) |
| IL (1) | IL254473B (fr) |
| MA (1) | MA41790B1 (fr) |
| MX (2) | MX2021008741A (fr) |
| MY (1) | MY197742A (fr) |
| PH (1) | PH12017501655B1 (fr) |
| PL (1) | PL3272750T3 (fr) |
| RU (1) | RU2762567C2 (fr) |
| SG (2) | SG11201707427TA (fr) |
| TW (2) | TWI775723B (fr) |
| WO (1) | WO2016148232A1 (fr) |
| ZA (1) | ZA201706882B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE057266T2 (hu) * | 2015-03-17 | 2022-05-28 | Nippon Chemiphar Co | Morfinán származék |
| EP3498711A4 (fr) | 2016-08-09 | 2020-01-22 | Nippon Chemiphar Co., Ltd. | Dérivé de morphinane |
| JP6840155B6 (ja) | 2016-09-16 | 2025-06-17 | 日本ケミファ株式会社 | モルヒナン誘導体のオピオイドδ受容体アゴニスト関連疾患の治療のための使用 |
| JP7283711B2 (ja) * | 2016-10-03 | 2023-05-30 | 学校法人星薬科大学 | モルヒナン誘導体を含む医薬組成物及びその鎮痛剤への使用 |
| EP4001280A4 (fr) * | 2019-07-19 | 2023-07-12 | Nippon Chemiphar Co., Ltd. | Procédé de production d'un dérivé du phénol |
| CA3146790A1 (fr) | 2019-07-19 | 2021-01-28 | Nippon Chemiphar Co., Ltd. | Procede de production d'un derive de morphinane |
| CA3192609A1 (fr) | 2020-08-28 | 2022-03-03 | Nippon Chemiphar Co., Ltd. | Procede de preparation d'un derive de morphinane a chaine principale formee d'ether diarylique utilisant un nouveau catalyseur au cuivre |
| CA3211977A1 (fr) * | 2021-02-26 | 2022-09-01 | Tokyo University Of Science Foundation | Composition pharmaceutique pour le traitement ou la prevention de troubles lies au stress |
| CN116997360A (zh) * | 2021-02-26 | 2023-11-03 | 学校法人东京理科大学 | 应激相关障碍的治疗或预防用医药组合物 |
| WO2025197843A1 (fr) * | 2024-03-18 | 2025-09-25 | 学校法人東京理科大学 | Composition pharmaceutique pour le traitement et la prévention de l'anhédonie |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005231995A (ja) | 1999-12-22 | 2005-09-02 | Meiji Seika Kaisha Ltd | オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物 |
| DE10161963A1 (de) | 2001-12-17 | 2003-07-03 | Johannes Schuetz | 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung |
| AR044010A1 (es) | 2003-04-11 | 2005-08-24 | Janssen Pharmaceutica Nv | Uso de derivados de 4-fenil-4- [1h-imidazol-2-il]- piperidina sustituidos como agonistas delta opioideos no peptidos selectivos, con actividad antidepresiva y ansiolitica |
| JP2008534679A (ja) | 2005-04-04 | 2008-08-28 | アストラゼネカ・アクチエボラーグ | 新規ジアザスピロアルカン類およびｃｃｒ８介在疾患の処置のためのそれらの使用 |
| WO2008001859A1 (fr) | 2006-06-30 | 2008-01-03 | School Juridical Person Kitasato Gakuen | AGONISTE DES RÉCEPTEURS δ DES OPIOÏDES |
| JP2010538094A (ja) | 2007-09-06 | 2010-12-09 | アレイ バイオファーマ、インコーポレイテッド | チロシンキナーゼ阻害剤としてのピラゾロピリジン類 |
| US8183371B2 (en) | 2009-10-30 | 2012-05-22 | Janssen Pharmaceutica Nv | Pyrazines as delta opioid receptor modulators |
| EP2525659B1 (fr) | 2010-01-19 | 2019-02-27 | Merck Sharp & Dohme Corp. | COMPOSÉS PYRAZOLO[1,5-a]PYRIMIDINES EN TANT QU'INHIBITEURS DE mTOR |
| CA2822453C (fr) | 2010-12-23 | 2019-04-02 | Phoenix Pharmalabs, Inc. | Nouveaux morphinanes utiles en tant qu'analgesiques |
| JP2014073964A (ja) | 2011-01-28 | 2014-04-24 | Kitasato Institute | モルヒナン誘導体 |
| ES2626983T3 (es) * | 2011-09-09 | 2017-07-26 | The Kitasato Institute | Derivado de morfinano |
| WO2014021273A1 (fr) * | 2012-07-30 | 2014-02-06 | 学校法人北里研究所 | Dérivés morphinane |
| TW201434836A (zh) | 2012-12-14 | 2014-09-16 | Purdue Pharma Lp | 包含氮之嗎啡喃衍生物及其用途 |
| EP2966074B1 (fr) | 2013-03-08 | 2018-07-25 | The Kitasato Institute | Dérivé de morphinane |
| HUE057266T2 (hu) * | 2015-03-17 | 2022-05-28 | Nippon Chemiphar Co | Morfinán származék |
| JP6840155B6 (ja) | 2016-09-16 | 2025-06-17 | 日本ケミファ株式会社 | モルヒナン誘導体のオピオイドδ受容体アゴニスト関連疾患の治療のための使用 |
-
2016
- 2016-03-17 HU HUE16765061A patent/HUE057266T2/hu unknown
- 2016-03-17 AU AU2016234222A patent/AU2016234222C1/en active Active
- 2016-03-17 ES ES16765061T patent/ES2904511T3/es active Active
- 2016-03-17 RU RU2017134286A patent/RU2762567C2/ru active
- 2016-03-17 JP JP2017506606A patent/JP6692345B2/ja active Active
- 2016-03-17 TW TW105108248A patent/TWI775723B/zh active
- 2016-03-17 SG SG11201707427TA patent/SG11201707427TA/en unknown
- 2016-03-17 US US15/558,026 patent/US10442802B2/en active Active
- 2016-03-17 MY MYPI2017703345A patent/MY197742A/en unknown
- 2016-03-17 EP EP21203556.2A patent/EP3974430A1/fr active Pending
- 2016-03-17 BR BR112017019805-3A patent/BR112017019805B1/pt active IP Right Grant
- 2016-03-17 MX MX2021008741A patent/MX2021008741A/es unknown
- 2016-03-17 DK DK16765061.3T patent/DK3272750T3/da active
- 2016-03-17 WO PCT/JP2016/058475 patent/WO2016148232A1/fr not_active Ceased
- 2016-03-17 PL PL16765061T patent/PL3272750T3/pl unknown
- 2016-03-17 KR KR1020237022162A patent/KR102813010B1/ko active Active
- 2016-03-17 CN CN202110578658.0A patent/CN113292559B/zh active Active
- 2016-03-17 KR KR1020177029778A patent/KR102551969B1/ko active Active
- 2016-03-17 MX MX2017011824A patent/MX384744B/es unknown
- 2016-03-17 SG SG10201907667RA patent/SG10201907667RA/en unknown
- 2016-03-17 TW TW111126713A patent/TWI778933B/zh active
- 2016-03-17 EP EP16765061.3A patent/EP3272750B1/fr active Active
- 2016-03-17 CN CN202110577382.4A patent/CN113292558A/zh active Pending
- 2016-03-17 CN CN201680016083.0A patent/CN107614500B/zh active Active
- 2016-03-17 CA CA2979023A patent/CA2979023C/fr active Active
- 2016-03-17 MA MA41790A patent/MA41790B1/fr unknown
-
2017
- 2017-09-11 PH PH12017501655A patent/PH12017501655B1/en unknown
- 2017-09-13 IL IL254473A patent/IL254473B/en unknown
- 2017-10-11 ZA ZA2017/06882A patent/ZA201706882B/en unknown
-
2019
- 2019-07-19 US US16/517,081 patent/US10995092B2/en active Active
-
2020
- 2020-04-10 JP JP2020071041A patent/JP2020117533A/ja not_active Ceased
- 2020-10-13 US US17/069,589 patent/US11643411B2/en active Active
- 2020-11-18 AU AU2020270503A patent/AU2020270503C9/en active Active
-
2022
- 2022-01-18 CY CY20221100041T patent/CY1124908T1/el unknown
- 2022-03-18 JP JP2022044083A patent/JP7375076B2/ja active Active
-
2023
- 2023-01-09 US US18/094,687 patent/US20230159530A1/en active Pending
- 2023-10-25 JP JP2023183221A patent/JP2024010098A/ja active Pending
-
2025
- 2025-06-10 JP JP2025096247A patent/JP2025131782A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41790B1 (fr) | Dérivé de morphinane | |
| MX2020011501A (es) | Compuestos novedosos. | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
| SV2017005384A (es) | Compuestos aminopirimidinilo | |
| MA28024A1 (fr) | Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2 | |
| MA32164B1 (fr) | Derive heterocyclique fusionne et son utilisation | |
| AR056043A1 (es) | Agonistas de receptores adrenergicos alfa2c funcionalmente selectivos | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR094272A1 (es) | Compuestos de diona ciclica activos como herbicidas, o derivados de los mismos, sustituidos por un fenilo que tiene un sustituyente que contiene alquinilo | |
| AR116713A1 (es) | COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3 | |
| MA53370B1 (fr) | Procédé et intermédiaires pour la préparation de bilastine | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| EA202192760A1 (ru) | Трициклические соединения | |
| MA50093B1 (fr) | Composé pentacyclique | |
| AR116906A1 (es) | Derivados de heteroarilo bicíclico | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
| MA41885B1 (fr) | Mélange d'additifs | |
| CO2022004391A2 (es) | Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4 | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| BR112022008647A2 (pt) | Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo | |
| MA41975B1 (fr) | Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer | |
| MA45887A1 (fr) | Cristal de dérivé de pyrido [3, 4-d] pyrimidine ou son solvate |